Generally, our study elucidates the abnormal SPHK1/S1P/S1PR3 axis in LAM progression and the effects of PF543 and TY52156 in antitumor therapy (Fig. 8). This evidence concerns the gene S1PR3 and lymphangioleiomyomatosis.